GFM
UTHR icon

GF Fund Management’s United Therapeutics UTHR Stock Holding History

GF Fund Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$455K Sell
840
-127
-13% -$71.5K 0.01% 221
2026
Q1 		$573K Buy
967
+122
+14% +$60.8K 0.01% 213
2025
Q4 		$412K Sell
845
-128
-13% -$59.6K 0.01% 236
2025
Q3 		$408K Sell
973
-170
-15% -$57.2K 0.01% 235
2025
Q2 		$328K Hold
1,143
– – 0.01% 281
2025
Q1 		$352K Buy
1,143
+206
+22% +$70.6K 0.01% 283
2024
Q4 		$331K Buy
+937
New +$344K 0.01% 253

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

GF Fund Management's UTHR Position: Q2 2026 in Review

GF Fund Management reduced its United Therapeutics (UTHR) stake by 13% in Q2 2026, selling an estimated $71.5K and leaving 840 shares worth $455K. The position accounts for 0.01% of the portfolio, ranked #221.

GF Fund Management first reported a position in UTHR in Q4 2024 and has held it in 7 quarters since. The position peaked at $573K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • GF Fund Management held 840 shares of United Therapeutics worth $455K as of Q2 2026.
  • GF Fund Management sold 127 United Therapeutics shares in Q2 2026, an estimated $71.5K.
  • United Therapeutics made up 0.01% of GF Fund Management's portfolio in Q2 2026, its #221 holding.
  • GF Fund Management first reported a position in United Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's United Therapeutics position peaked at $573K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.